Calls for papers
-
Kamada has submitted a Marketing Authorization Application for its inhaled alpha-1 antitrypsin (AAT) therapy for the treatment of AAT deficiency to the European Medicines Agency, and the filing EMA has validated the application, the company… Read more . . .
-
The upcoming RDD meeting to be held April 17-21, 2016 at the Westin Kierland Resort in Phoenix, AZ will offer several new features in addition to the usual scientific presentations, posters, exhibition, and networking opportunities. For the… Read more . . .
-
Boehringer Ingelheim and Propeller Health have announced a new partnership that will allow COPD and asthma patients using Respimat inhalers “to enroll at select US health systems in a new program that is designed to… Read more . . .
-
The FDA has granted Qualified Infectious Disease Product (QIDP) designation to Raptor Pharmaceutical’s MP-376 inhaled levofloxacin for the treatment of chronic P. aeruginosa lung infections in patients with cystic fibrosis, non-cystic fibrosis bronchiectasis (BE), and… Read more . . .
-
A study published online ahead of print in the Annals of the American Thoracic Society (AnnalsATS) finds that a “teach-to-goal” inhaler education strategy reduced rescue inhaler misuse to 11% compared to 60% for a “brief… Read more . . .
-
Apotex has launched a generic version of Merck’s Nasonex mometasone furoate nasal spray in the United States, the company said. In June 2012, A US District Court judge upheld a Merck patent on mometasone furoate… Read more . . .
-
Verona Pharma has announced positive data from a Phase 2a study of RPL554, an inhaled PDE3/PDE4 inhibitor for the treatment of acute exacerbations in COPD patients. According to the company, asthma patients who received the… Read more . . .
-
The US Department of Health and Human Services has announced that a grant of up to $200,000 is available for “Assessment of Intersubject Variability in Small Airway Delivery with Oral Inhalation Drug Products.” One grant… Read more . . .
-
Aradigm Corporation has announced that the EMA will review an Aradigm MAA for Pulmaquin inhaled liposomal ciprofloxacin under the centralized authorization procedure. According to the company, “Aradigm requested, and was granted, the centralized pathway on… Read more . . .
-
Inhaled drug manufacturers Vectura and Skyepharma have announced a merger agreement in which Vectura will acquire Skyepharma for a total of £441 million ($638 million). Both boards have approved the merger. Vectura previously acquired Activaero… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland